Leaming appointed to Biogen Idec board of directors
CAMBRIGDE, Mass. Biogen Idec has appointed Nancy Leaming to its board of directors.
For twenty years, Leaming has served in several executive positions at Tufts Health Plan, including president and chief executive officer from 2003-2005, president and chief operating officer from 1997-2003 and chief operating officer from 1986-1997.
“I’m very pleased that Nancy Leaming is joining our Board of Directors,” said Bruce Ross, Biogen Idec’s chairman. “With extensive experience in the healthcare sector, Nancy has the proven business and leadership skills to help Biogen Idec drive our strategic plan forward in the years ahead.”
Leaming has served in various capacities on both commercial and non-profit boards. She is currently a member of the boards of directors at Hologic Inc., where she chairs the audit committee, Edgewater Technology, the Massachusetts Taxpayers Foundation and the American Red Cross of Massachusetts.
Taro settles patent suit, launches generic Trileptal
HAWTHORNE Taro announced Wednesday that it has settled a patent lawsuit with Novartis and will launch oxcarbazepine tablets, the generic version of Novartis’ Trileptal. Oxcarbazepine tablets are indicated to treat seizures.
The litigation with Novartis centered on Taro’s Paragraph IV certification challenging Novartis’ patent protection on Trileptal. On Nov. 15, 2007, Taro received Food and Drug Administration approval for its abbreviated new drug application for oxcarbazepine tablets in 150 mg, 300 mg and 600 mg strengths, but the company waited to launch the drug until the lawsuit was settled.
According to Taro, Trileptal currently has annual U.S. sales of approximately $700 million.
Sciele to launch six medications in 2008
ATLANTA In addition to Sciele’s announcement last week, reported in Drug Store News, that it will launch its new Sular formulation during the first quarter of 2008, the company also announced plans to launch five other drugs this year:
- two new dosages of fenofibrate for the treatment of mixed dyslipidemia
- Prandin for Type 2 diabetes
- PrandiMet for Type 2 diabetes (pending FDA approval)
- a head lice asphyxiation product (pending FDA approval)
- a women’s health product
Sciele reaffirmed its full-year guidance at the JPMorgan 26th Annual Health Care Conference yesterday. As previously announced, full-year 2007 revenue is expected to range between $375 million and $385 million. The company expects full-year 2008 revenues to range from $440 million to $455 million.